Catalent Inc (CTLT) stock saw a modest uptick, ending the day at $63.24 which represents a slight increase of $1.00 or 1.61% from the prior close of $62.24. The stock opened at $62.5 and touched a low ...

The proposed buyout of contract drug manufacturer Catalent won’t raise competition concerns, the European Commission said.

Bioprocessing technology has a role to play in helping developers exert greater control over production processes.

Novo Nordisk parent’s huge manufacturing deal is one step closer to closing. Meanwhile, Nobel Prize winners urge senators to ...

Catalent (CTLT) stock rises on reports of imminent $16.5 billion sale to Novo Holdings with FTC approval and EU Commission ...

By far, the largest acquisition of 2024 was Novo Holdings' yet-to-be-closed buyout of manufacturer Catalent at $16.5 billion.

Robert W. Baird has recently raised Catalent Inc (CTLT) stock to Outperform rating, as announced on November 16, 2023, according to Finviz. Earlier, on September 5, 2023, Argus had raised the stock ...

QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic ...

New York-based Citi is in the midst of a restructuring to focus on the firm’s key businesses, which it identified as trading, ...

In the U.S., the chorus of opposition against the proposed buyout continues to grow and now includes the CEOs of Roche and ...

The BIOSECURE Act, which would restrict drugmakers from using key Chinese contract manufacturers, was left out of a defense ...